### [Ghobrial et al. Page 344][1] Preclinical studies have revealed CXCR4 as a promising target in multiple myeloma (MM). In a Phase Ib/II clinical trial, Ghobrial and colleagues assessed ulocuplumab, a first-in-class anti-CXCR4 antibody, combined with lenalidomide or bortezomib plus dexamethasone

中文翻译：

---

本期精选文章

### [Ghobrial等。Page 344] [1]临床前研究表明CXCR4是多发性骨髓瘤（MM）的有希望的靶标。在Ib / II期临床试验中，Ghobrial及其同事评估了抗CXCR4一流抗体ulocuplumab，与来那度胺或硼替佐米加地塞米松联合使用